UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: February 27, 2015
(Date of earliest event reported)
REVA MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 000-54192 |
| 33-0810505 |
(State or other jurisdiction |
| (Commission |
| (I.R.S. Employer |
of incorporation) |
| File Number) |
| Identification No.) |
5751 Copley Drive, San Diego, CA |
| 92111 |
(Address of principal executive offices) |
| (Zip Code) |
(858) 966-3000 |
(Registrant’s telephone number, including area code) |
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On February 27, 2015 (Australian Eastern Daylight Time), REVA Medical, Inc. (the “Company”) issued an ASX announcement containing its preliminary financial results for the fiscal year ended December 31, 2014. A copy of the ASX announcement is attached hereto as Exhibit 99.1. The preliminary results are currently under audit by the Company’s auditors, Grant Thornton LLP, with final audited results to be released in the Company’s Form 10-K to be filed with the Securities and Exchange Commission.
On February 27, 2015 (Australian Eastern Daylight Time), the Company also lodged its Preliminary Final Report on Appendix 4E for the year ended December 31, 2014 with the Australian Securities Exchange (“ASX”), a copy of which is attached hereto as Exhibit 99.2. The Preliminary Final Report is prepared in U.S. dollars.
Item 7.01 Regulation FD Disclosure
See Item 2.02 above.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit |
|
|
Number |
| Description or Exhibits |
99.1 |
| ASX Announcement dated February 27, 2015* |
99.2 |
| Preliminary Final Report on Appendix 4E for the year ended December 31, 2014* |
* Exhibit 99.1 and Exhibit 99.2 are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall they be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| REVA Medical, Inc. |
|
|
Date: February 27, 2015 | /s/ Katrina L. Thompson |
| Katrina L. Thompson |
| Chief Financial Officer |
| (principal financial and accounting officer) |